CorMedix Inc. has announced the acquisition of Melinta Therapeutics. According to the company announcement CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The company is acquiring Melinta Therapeutics, a strategic move that will transform CorMedix into a diversified specialty pharmaceutical organization with a strong presence in acute care settings. This acquisition is expected to expand and diversify CorMedix’s commercial product portfolio, adding seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential. The transaction is anticipated to be accretive to EPS in the near term, with double-digit accretion expected in 2026, and pro forma 2025 combined revenues are estimated to be between $305 million and $335 million.

To learn more about CorMedix Inc., visit https://www.cormedix.com
Company LinkedIn Page: https://www.linkedin.com/company/cormedix-inc-/

Company Contact:

CorMedix Inc.
300 Connell Drive, Suite 4200 Berkeley Heights, NJ 7922
908-517-9500

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.